Gemcitabine uptake in glioblastoma multiforme: Potential as a radiosensitizer

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 182-187

  Sigmond, J ^a   Honeywell, R J ^a   Postma, T J ^a   Dirven, C M F ^b   de Lange, S M ^a   van der Born, K ^a   Laan, A C ^a   Baayen, J C A ^a   van Groeningen, C J ^a   Bergman, A M ^c   Giaccone, G ^d   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Glioblastoma multiforme; Radiosensitizer

Indexed keywords

DEAMINASE; DEOXYCYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; GEMCITABINE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME METABOLISM; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIOSENSITIZATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; BIOPSY; BRAIN NEOPLASMS; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FEMALE; FLOXURIDINE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDE DEAMINASES; RADIATION-SENSITIZING AGENTS;

EID: 58949102224     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn543     Document Type: Article

References (38)

1. Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML. Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 1998; 174: 629-632.
2. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004; 64: 6892-6899.
3. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Sneed PK, Gutin PH, Larson DA et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994; 29: 719-727.
5. Wallner KE, Galicich JH, Krol G et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405-1409.
6. van Nifterik K, Van den Berg J, Stalpers L et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Rad Oncol Biol Phys 2007; 69: 1246-1253.
7. Shewach DS, Lawrence TS. Nucleoside radiosensitizers. In Peters GJ (ed): Deoxynucleoside Analogues in Cancer Therapy. Humana Press 2006; 289-330.
8. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005; 10: 34-51.
9. Toschi L, Finocchiaro G, Bartolini S et al. Role of gemcitabine in cancer therapy. Future Oncol 2005; 1: 7-17.
10. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002; 5: 19-33.
11. Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993; 46: 762-766.
12. Heinemann V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-572.
13. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3-15.
14. Pauwels B, Korst AE, Lambrechts HA et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 2006; 58: 219-228.
15. van Moorsel CJ, Kroep JR, Pinedo HM et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999; 10: 441-448.
16. Kroep JR, Giaccone G, Voorn DA et al. Gemcitabine and paclitaxel; pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J Clin Oncol 1999; 17: 2190-2197.
17. Tremblay GC, Jimenez U, Crandall DE. Pyrimidine biosynthesis and its regulation in the developing rat brain. J Neurochem 1976; 26: 57-64.
18. Peters GJ, Veerkamp JH. Pyrimidine metabolism in rat brain cortex and liver. Adv Exp Med Biol 1984; 165A: 531-534.
19. Nakagawa S, Guroff G. The uptake of purines by rat brain in vivo and in vitro. J Neurochem 1973; 20: 1141-1149.
20. Peters GJ, Van Groeningen CJ, Laurensse E et al. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 1987; 20: 101-108.
21. Esumi Y, Mitsugi K, Takao A et al. Disposition of gemcitabine in rat and dog after single and multiple dosings. Xenobiotica 1994; 24: 805-817.
22. Stewart DJ, Molepo JM, Green RM et al. Factors affecting platinum concentrations n human surgical tumour specimens after cisplatin. Br J Cancer 1995; 71: 598-604.
23. Peters GJ, Clavel M, Noordhuis P et al. Clinical phase I and pharmacology study of gemcitabine (2′, 2′-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother 2007; 19: 212-221.
24. Peters GJ, Laurensse EJ, Leyva A, Pinedo HM. Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities. Clin Chim Acta 1986; 158: 193-198.
25. van der Wilt CL, Kroep JR, Loves WJ et al. Expression of deoxycytidine kinase in leukemic cells compared with solid tumor cell lines, liver metastases and normal liver. Eur J Cancer 2003; 39: 691-697.
26. Sigmond J, Kroep JR, Loves W et al. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity. Cancer Lett 2004; 213: 173-179.
27. Kroep JR, Loves WJ, van der Wilt CL et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002; 1: 371-376.
28. Ruiz van Haperen VWT, Veerman G, Braakhuis BJM et al. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 1993; 29A: 2132-2137.
29. Honeywell R, Laan AC, Van Groeningen CJ et al. The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J. Chromatogr B 2007; 847: 142-152.
30. Madani S, Baillon J, Fries J et al. Pyrimidine pathways enzymes in human tumors of brain and associated tissues: Potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine. Eur J Cancer Clin Oncol 1987; 23: 1485-1490.
31. Weller M, Streffer J, Wick W et al. Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. Cancer 2001; 91: 423-427.
32. Gertler SZ, MacDonald D, Goodyear M et al. NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 2000; 11: 315-318.
33. Lawrence TS, Eisbruch A, McGinn CJ et al. Radiosensitization by gemcitabine. Oncology (Williston Park) 1999; 13: 55-60.
34. Genc M, Castro Kreder N, Barten-van Rijbroek A et al. Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids. J Cancer Res Clin Oncol 2004; 130: 45-51.
35. Gregoire V, Rosier JF, De Bast M et al. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiother Oncol 2002; 63: 329-338.
36. Pauwels B, Korst AE, Pattyn GG et al. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer 2006; 6: 142.
37. Apparaju SK, Gudelsky GA, Desai PB. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: An in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother Pharmacol 2008; 61: 223-229.
38. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.